Digital Repository

Rationale for a new low-dose triple single pill combination for the treatment of hypertension

Show simple item record

dc.contributor.author Rodgers, A.
dc.contributor.author Salam, A.
dc.contributor.author Cushman, W.
dc.contributor.author de Silva, A.
dc.contributor.author Tanna, G.L.D.
dc.contributor.author Gnanenthiran, S.R.
dc.contributor.author Grobbee, D.
dc.contributor.author Narkiewicz, K.
dc.contributor.author Ojji, D.
dc.contributor.author Oparil, S.
dc.contributor.author Poulter, N.
dc.contributor.author Schlaich, M.P.
dc.contributor.author Schutte, A.E.
dc.contributor.author Spiering, W.
dc.contributor.author Williams, B.
dc.contributor.author Wright, J.T.Jr.
dc.contributor.author Whelton, P.
dc.date.accessioned 2024-02-27T06:13:12Z
dc.date.available 2024-02-27T06:13:12Z
dc.date.issued 2024
dc.identifier.citation Global Heart.2024;19(1):18 en_US
dc.identifier.issn 2211-8160 (Print)
dc.identifier.issn 2211-8179 (Electronic)
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/27617
dc.description Indexed in MEDLINE. en_US
dc.description.abstract Two recent large trials showed the potential of single pill combinations (SPCs) with ≥3 low-dose components among people with hypertension who were untreated or receiving monotherapy. In both trials, these 'hypertension polypills' were superior to usual care, achieving >80% BP control without increasing withdrawal due to side effects. However, there are no such products available for prescribers. To address this unmet need, George Medicines developed GMRx2 with telmisartan/amlodipine/indapamide in three strengths (mg): 10/1.25/0.625, 20/2.5/1.25; 40/5/2.5. Two pivotal trials are ongoing to support FDA submission for the treatment of hypertension, including initial treatment. These assess efficacy and safety of GMRx2 compared to: placebo, and each of the three possible dual combinations. Regulatory submissions are planned for 2024, with the aim of providing access to GMRx2 in developed and developing regions. Wider implementation of GMRx2-based treatment strategies will be guided by further research to inform access and appropriate scale up. en_US
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.subject hypertension en_US
dc.subject polypill en_US
dc.subject blood pressure en_US
dc.subject single pill combination en_US
dc.subject fixed dose en_US
dc.title Rationale for a new low-dose triple single pill combination for the treatment of hypertension en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account